Lin28A activates androgen receptor via regulation of c-myc and promotes malignancy of ER-/Her2 + breast cancer
Dulaglutide and Tirzepatide Litigation British Columbia Class Action On February 11, 2026, Siskinds filed a proposed class action in the Supreme Court of British Columbia, alleging that dulaglutide drugs (Trulicity) and tirzepatide drugs (Mounjaro, Zepbound) manufactured and marketed by the Eli Lilly group of pharmaceutical companies were defective, and that the manufacturers failed to adequately warn users, and their health care providers, that semaglutide drugs increase the risk of serious complications, including gallbladder disorders, severe gastrointestinal injuries (including gastroparesis, or stomach paralysis), blood clots, aspiration during surgery, necrotizing pancreatitis, malnutrition, and vision loss (non-arteritic anterior ischemic optic neuropathy)
Early movement helps maintain muscle mass, restore range of motion, reduce stiffness, and get the body trusting the joint again
Feel revitalized with our Mobile IV Therapy, all in the comfort of your chosen location
This trial is critical because it evaluates retatrutide's dual benefits: weight reduction and glycemic control